Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Pharmaceuticals Stock (IONS)

• Ionis Pharmaceuticals recently reported that pelacarsen did not reduce major cardiovascular events in a large Novartis led outcomes trial, which removed a previously anticipated drug royalty source tied to Lp(a) lowering.
• This setback arrives while Ionis Pharmaceuticals is already managing revenue shrinkage and net losses. This increases execution pressure on its APOC3, neurology and rare disease franchises to support the business over time.
• We will now look at how Ionis Pharmaceuticals' investment narrative is affected by the pelacarsen trial failure and the reduced cardiovascular upside.

Scan beyond Ionis Pharmaceuticals and see how other turnaround biotech stories with stronger balance sheets or cleaner revenue profiles stack up by reviewing the curated list of solid balance sheet and fundamentals (24 results).

Ionis Pharmaceuticals Investment Narrative Recap

For Ionis Pharmaceuticals to make sense in a portfolio, you need to be comfortable owning a loss making biotech that is trying to turn a broad RNA platform into a focused, commercial story. The pelacarsen outcome removes a potential future royalty stream but does not change that near term execution is mostly about APOC3, neurology and rare disease launches.

The immediate swing factor now looks like how quickly TRYNGOLZA, DAWNZERA and ZANVASTRO builds can offset shrinking collaboration revenue and persistent net losses. The biggest risk is that setbacks like eplontersen and pelacarsen erode confidence in the RNA platform, which could weigh on future partnered economics and extend the path to profitability.

In the context of pelacarsen, the most relevant prior update is the eplontersen failure in ATTR cardiomyopathy, where strong TTR lowering did not translate into benefit on a composite endpoint. Together, these outcomes underline that target knockdown data alone is not enough for this platform to create durable cardiovascular or cardiometabolic franchises.

For you as a shareholder, that pushes more weight onto the APOC3 and neurology engines as the practical catalysts to watch. It also elevates partnered programs like bepirovirsen, sefaxersen and Biogen’s diranersen as important proof points that Ionis Pharmaceuticals can still turn its RNA toolkit into meaningful, de risked royalty streams despite recent cardiovascular disappointments.

Ionis Pharmaceuticals' current analyst narrative points to revenues of US$2.2b and earnings of US$259.0m by 2029, built on an assumed 36.1% yearly revenue growth rate and a shift from today’s reported earnings loss of US$565.2m to the 2029 consensus. That path implies an earnings swing of roughly US$824m from the loss today to the projected profit level in 2029.

Uncover why Ionis Pharmaceuticals' fair value indicates a 113% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

One alternate angle on Ionis Pharmaceuticals focuses on bullish neurology catalysts rather than cardiometabolic setbacks. The most optimistic analysts were modelling revenue of about US$3.0b and earnings of US$712.1m by 2029 before this pelacarsen news. That is a very different story. You should expect those projections and opinions to evolve as events unfold.

Explore 3 other Ionis Pharmaceuticals fair value estimates, including one that suggests potential upside of up to 647% from the current price.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment outcomes rarely come from following the herd, so consider trusting your own analysis.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for Ionis Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Looking For More Ideas Beyond Ionis Pharmaceuticals?

If the Ionis Pharmaceuticals story leaves you wanting a broader watchlist, the Simply Wall St Screener can help you quickly surface other opportunities that better fit your risk tolerance and income goals.

• If income and resilience matter most to you, focus on companies described as 8 dividend fortresses that may support a more dependable cash flow profile from your portfolio.
• For investors who care first about downside protection, filter for businesses flagged as 29 resilient stocks with low risk scores and compare their risk profiles against Ionis Pharmaceuticals.
• If you want potential upside but still care about balance sheet strength, start with the 19 high quality undiscovered gems that combine quality fundamentals with less crowded investor attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com